[Featured Stock] "Overseas Expansion Expectations" HK Innoen, Up 3.10%

Expectations for the US and European market entry of the core product K-CAB have increased, leading to a rise in HK Innoen's stock price. As of 9:21 AM on the 23rd, HK Innoen was trading at 49,900 KRW, up 1,500 KRW (3.10%) from the previous trading day.

On the same day, Korea Investment & Securities gave HK Innoen a "Buy" rating with a target price of 90,000 KRW, stating that "the company is receiving greater attention with the announcement of the US Phase 3 clinical trial results." Researcher Wi Haeju from Korea Investment & Securities said, "As the domestic acid secretion inhibitor market grows, K-CAB's sales are also expected to increase," adding, "Attention should be paid to the announcement of the US Phase 3 clinical trial data for non-erosive reflux disease in the fourth quarter. The likelihood of clinical success is very high, as K-CAB demonstrated superior efficacy compared to placebo in the Korean Phase 3 trial, contributing to market expansion."

This year's expected sales are 958.8 billion KRW, and expected operating profit is 101.2 billion KRW, representing increases of 15.7% and 53.4% respectively compared to the previous year. Researcher Wi stated, "Domestic sales of K-CAB are expected to grow by 51.1%, contributing to operating profit growth," and added, "The announcement of the US Phase 3 clinical trial results is expected to raise expectations not only for successful entry into the US market but also for the selection of a European partner."

This content was produced with the assistance of AI translation services.